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Summary We report a constitutional point mutation ofcodon 278 in exon 8 of the TP53 gene that has not yet
been described as a germ-line mutation. A 52-year-old female developed multiple primary malignancies
(liposarcoma, breast cancer, malignant histiocytoma, occult adenocarcinoma). The mutation found in her
tumour and peripheral blood lymphocyte DNA is a cytosine to thymine transition at the second position of
codon 278 resulting in an amino acid exchange from proline to leucine in the DNA-binding domain.
Evaluation ofthe patient's family revealed that both ofher sons were affected by the same mutation. Although
the patient's mother had died already, we were able to demonstrate by polymorphic microsatellite analysis that
the defective allele originated from the maternal side. As four brothers and one sister had inherited the same
allele, which however was wild type, we were able to show that the mutation must have occurred in the germ
cells of the patient's mother and that it may therefore be called de novo. This explains the lack of a high cancer
incidence in the family history. All tumours tested showed positive immunohistochemical staining for p53. Loss
of heterozygosity was found in five of seven tumours, one showing chromosome 17 monosomy.
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According to Knudson's two-hit hypothesis, the most striking
difference between sporadic and inherited cancer is that in the
latter the number of steps in oncogenesis is reduced by one.
Genes mutated in hereditary cancer are tumour-suppressor
genes. Germ-line mutations of these genes predispose carriers
to cancer development. These 'family cancer genes' are called
'recessive' cancer genes since one normal allele is enough to
protect against cancer (Knudson, 1985). The second hit,
resulting in cancer development is supposed to be either an
allelic deletion leading to a loss of heterozygosity (LOH), a
second point mutation occurring in the wild-type allele or a
functional inactivation of the wild-type protein (Vogelstein
and Kinzler, 1992).
Lane (1992) described the TP53 gene as a 'guardian of the
genome', acting to protect cells from genetic damage by
inducing either DNA repair of apoptosis, which appear to be
important mechanisms for eliminating abnormal cells.
Inactivation of this cell cycle control function of p53 either
by mutations or complex formation with certain proteins may
result in accumulation of mutated p53 protein and in genetic
instability, a key factor in neoplastic pathogenesis and
tumour progression.
TP53 mutations were initially identified as the major
genetic basis of the Li-Fraumeni and the Li-Fraumeni-like
syndrome (Malkin et al., 1990; Srivastava et al., 1990), an
autosomal dominant predisposition to cancer development
(Li and Fraumeni, 1969; Birch et al., 1994). In such families,
cancer development occurring at unusually early ages appears
to segregate with the presence of a germ-line TP53 mutation.
In this study we describe a 52-year-old patient who
developed multiple primary tumours reminiscent of a
constitutional TP53 mutation. Since it has been shown that
the highly conserved regions of TP53 are mutational hotspots
both in sporadic and in hereditary cancers (Soussi et al.,
1990; Levine et al., 1991; Caron de Fromentel and Soussi,
1992) we investigated the coding sequences of exons 5-8,
applying a combination of temperature gradient gel
electrophoresis (TGGE) and direct sequencing. To demon-
strate a possible p53 overexpression, the patient's tumours
were analysed immunohistochemically. Analysis of micro-
satellite polymorphisms and fluorescence in situ hybridisation
(FISH) were used to detect possible allelic imbalances, such
as deletions at the TP53 locus, aberrations of the
chromosome 17 copy number and intratumoral heterogene-
ity. Furthermore, we screened all first and second degree
family members alive for TP53 mutations and performed
haplotype analysis. Genetic and immunohistochemical find-
ings are reported.
Methods
DNA extraction
For DNA extraction, two 30 gim paraffin sections of each
tumour were treated as described (Speiser et al., 1996).
Polymerase chain reaction and temperature gradient gel
electrophoresis
Four regions of the TP53 gene corresponding to exons 5-8
were amplified by PCR. Fragment I comprises exon 5, intron
5 (81 bp) and exon 6; fragment II comprises exon 5, fragment
III exon 7 and fragment IV exon 8. Primer sequences were 5'-
CGC CCG CCG CGC CCC GCG CCC GCC CCG CCG
CCC CCG CCC CTT CCT CTT CCT GCA GTACTC C-3'
(sense primer, fragment I and II); 5'-AGT TGC AAA CCA
GAC CTC AGG-3' (antisense, primer, fragment I); 5'-GCC
CCA GCT GCT CAC CAT CGC T-3' (antisense primer,
fragment II); 5'-CGC CCG CCG CGC CCC GCG CCC
GCC CCG CCG CCC CCG CCC CGT GTT GTC TCC
TAG GTT GGC-3' (sense primer, fragment III); 5'-CAA
GTG GCT CCT GAC CTG GAG-3' (antisense primer,
fragment III); 5'-TGG TAA TCT ACT GGG ACG GAA
CAG C-3' (sense primer, fragment IV); 5'-CGC CCG CCG
CGC CCC GCG CCC GCC CCG CCG CCC CCG CCC
CTT ACC TCG CTT AGT GCT CC-3' (antisense primer,
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fragment IV). Primer sequences were chosen from the TP53
cDNA sequence (Zakut Houri et al., 1985). The sense primers
contained the sequence for a previously described 40 bp 'GC-
clamp' (Sheffield et al., 1989). Approximately 5 pl of the
DNA solution extracted as described above were used as
template for PCR. Reactions were performed in a total
volume of 50 pl in PCR-buffer containing 50 pmol of each
primer, 250 pM each dNTP and 0.25 u 'HiTaq' polymerase
(ViennaLab) for 30 cycles at 94°C (30 s), 62°C (30 s) and
72°C (45 s) and a final extension time of 5 min at 720C in a
Perkin Elmer Cetus 9600 DNA thermal cycler (Perkin Elmer,
Norwalk, CT, USA). PCR products were analysed in a 4%
(3/1 NuSieve/GTG-Agarose) agarose gel (FMC BioProducts,
Rockland, ME, USA).
Gels (19 x 19x 0.1 cm) for TGGE contained 8%
acrylamide and 8 M urea in a MOPS/EDTA buffer (20 mM
MOPS, 1 mM EDTA, pH 8.0) and were polymerised with
0.015% (w/v) ammonium persulphate and 0.17% (v/v)
A,N,N',NV-tetramethylethylenediamine. A total of 10 pl of
1:10 diluted PCR products were loaded onto the gel at
starting positions at the following temperatures: 430C for
fragments I and III, 48°C for fragment II and 460C for
fragment IV. Gels were run at 6 W (10 V cm-1) at 20°C for
15 min to allow entering of the samples into the gel at native
conditions. Then, a temperature gradient (TI = 30°C and
T2 = 700C) was superimposed on the gel parallel to the
electric field. Running times at 7.5 W (8 V cm-1) were
30 min. After electrophoresis, the gels were silver stained.
Microdissection and analysis of microsatellite polymorphisms
To enrich for tumour cells, 8 pm sections of formalin-fixed
paraffin-embedded tumours were subjected to microdissection
as described (Speiser et al., 1996).
Microsatellite analysis was performed for highly poly-
morphic dinucleotide repeat polymorphism at the loci TP53
(Jones and Nakamura 1992) and D17S786 (Gyapay et al.,
1994) with primer and conditions described there.
RFLP analysis
For the analysis of the intragenic RFLP (exon 4, BstUl) a
259 bp fragment was amplified by PCR and analysed on a
4% (3/1 NuSieve/GTG-Agarose) agarose gel as described by
Greenwald et al. (1992).
Immunohistochemistry
Sections (3 pm) were cut, deparaffinised and fixed on poly-L-
lysine-coated slides at room temperature. The sections were
stained with high-affinity anti-p53 monoclonal antibody DO-
1 (Vojtesek et al., 1992) using the staining protocol previously
described by Midgly et al. (1992) with the difference in the
streptavidin-biotin step (Biogenex Super Sensitive system
was used instead of Vector kit). 3,3-diaminobenzidine in
0.03% nickel sulphate was used as chromogen. In addition, a
further three monoclonal antibodies to p53 protein, i.e.
BP53.12, PAb 421, DO-7, and anti-p53 rabbit antiserum CM-
1, were used in parallel for the comparisons but the results
owing to minor difference in the staining intensity as
compared with DO-1 are not presented in detail.
Fluorescence in situ hybridisation
Dissociation of nuclei was as previously described (Sauter et
al., 1995a). The chromosome 17 centromere probe pl7H8
was digoxigenated by nick translation. Cells on slides were
denatured in 70% formamide/2 x sodium saline citrate
(SSC) (1 x SSC is 0.15 M sodium chloride, 0.015 M sodium
citrate), pH 7, at 75°C. The hybridisation mixture (10 Ml)
consisted of 30 ng of the centromere probe and 10 ng
unlabelled sonicated herring sperm DNA in 55% forma-
mide, 10% dextran sulphate and 2 x SSC (pH 7). After
hybridisation the slides were washed in 55% formamide/2 x
SSC, pH 7 at 45°C. Immunohistochemical probe detection
using FITC-conjugated sheep anti-digoxigenin (Vector) and
FITC-conjugated sheep anti-digoxigenin (Sigma) was de-
scribed previously (Sauter et al., 1995a). For each case, the
centromere 17 count was scored in 100 cells. Monosomic cell
counts below 10% do not indicate allelic loss, since this can
also be found in normal tissue and is generally attributed to
an inefficient hybridisation.
Results
Patient characteristics
The 52-year-old female patient had developed multiple
primary malignancies (Table I), including liposarcoma of
the left arm (TI) at age 40, Paget's disease and a concomitant
intraductal carcinoma of the left breast (T2) at 42, Paget's
disease and a concomitant ductal carcinoma in situ of the
right breast (T3) at 45, two independent malignant
histiocytomas of the biceps muscle of the left arm (T4) at
48 and of the pelvis (T5) at 49. One year later, when she was
operated on for a pelvic recurrence of histiocytoma (T6), a
metastasis of an adenocarcinoma of unknown origin was
found in the omentum majus (T7).
Detection of a TP53 germ-line mutation
To screen lymphocyte and tumour DNA for mutations in the
TP53 gene, regions spanning exons 5 to 8 were amplified by
polymerase chain reaction (PCR). PCR products were
subjected to TGGE analysis to detect bands with altered
electrophoretic mobility. All tumours exhibited a band
pattern that was in line with a possible mutation in exon 8.
This pattern was also found in the DNA of the patient's
peripheral blood lymphocytes (PBLs), indicating that the
mutation was constitutional (Figure 1). All PCR products
exhibiting this band pattern were directly sequenced. At
position 2 in codon 278 a cytosine to thymine (C--T)
Table I LOH determined by microsatellite polymorphisms and TGGE; p53 immunohistochemistry
expressed as staining intensity and percentage of positive nuclei
Loss of heterozygosity p53 staining Positive
Tumours TGGE TP53 D17S768 Intensity nuclei (%)
Ti + + + Strong >50%
T2 + Strong >50%
T3 Strong >50%
T4 + + + ND
T5 + + + Weak 50%
T6 + + + Strong 10%
T7 Weak <20%
TI, liposarcoma, arm left; T2, breast cancer, left; T3, breast cancer, right; T4/5, maligant histiocytoma, arm
left/pelvis; T6, pelvic recurrence of histiocytoma; T7, metastasis adenocarcinoma; Positive nuclei (%),
percentage ofp53-positive stained nuclei; +, LOH; -, no LOH; ND, not done.A constitutional de novo mutadon in exon 8 of the p53 gene
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Figure 1 TGGE analysis of exon 8-specific PCR products of all family members analysed (a) and the various tumours of the
affected patient. The affected patient and both her sons carry a point mutation resulting in denaturation of the PCR products at a
lower melting temperature, whereas all other family members are characterised by wild-type homoduplex bands only. All tumours
exhibited the same band pattern, the mutated homoduplex bands being dominant in tumours TI, T4, T5 and T6 indicating LOH
affecting exon 8.
transition was detected, which resulted in an amino acid
exchange from proline to leucine in the DNA-binding domain
(Cho et al., 1994) of the p53 protein.
p53 overexpression in the tumours
The results of immunohistochemistry are shown in Table I.
The p53-positive nuclear reaction was detected in all tumour
specimens tested regardless of the histological type of the
malignancy. Any positive staining was observed in the
stroma.
Family screening and haplotype analysis
Exact construction of the patient's pedigree (Figure 2) did
not reveal a high cancer incidence in the family history. The
patient's mother had died of an unknown disease at age 50.
One sister of her eight siblings had died of post-operative
thromboembolism. DNA from PBLs of the patient's family
was subjected to PCR-TGGE analysis of exon 8, which
revealed that her daughter, five brothers, two sisters, father
and aunt (maternal side) harboured wild-type alleles only.
Both of her sons, however, displayed the same band pattern
as their mother (Figure 1) and direct sequencing of the PCR
products showed that they had inherited the mutant allele.
To study haplotype associations (Figure 2), family members
were typed using the microsatellite polymorphisms at or near
TP53 (D17S768, TP53) and an intragenic RFLP (exon 4,
BstUl) (data not shown). We were able to demonstrate that
the defective allele originated from the maternal side because
the patient's aunt, four of her brothers and one of her sisters
had inherited the same allele, which however, was wild-type.
The patient's two sons had also inherited this allele, but in
the mutant form.
Allelic imbalance in the tumours
In four tumours we detected LOH both at TP53 and at
D17S768 (Table I, Figure 3). This was in line with the
observation that on TGGE analysis the mutated homoduplex
band was stronger than the wild-type homoduplex band
(Figure 1), indicating that LOH directly affected the TP53
gene. In tumour T2, LOH was found only at the
microsatellite marker TPS3 (imbalance factor of 2.1). In
tumours T3 and T7, no LOH was detectable. All tumour
DNA analysed was derived from archival material and care
was taken to maximise the number of tumour cells scraped
off the slides for PCR analysis. LOH in each tumour involved
loss of the allele inherited from the patient's father (Figure 3).
The concordant results of TGGE and microsatellite analysis
are a true indication of tumour DNA status and are not an
artefact of PCR.
Furthermore, we applied FISH with a centromere probe to
evaluate the chromosome 17 count. Tissue blocks from four
tumours containing more than 60% tumour cells were
considered adequate for FISH analyses. Only the local
recurrence of the malignant pelvic histiocytoma (T6) showed
a monosomic population of 41%, further corroborating the
finding of LOH for this tumour. There was a considerable
chromosome 17 heterogeneity on two of four tumours
examined by FISH. The malignant pelvic histiocytoma (T5)
itself contained two polysomic populations greater than 5%
(chromosome 17 centromere count n=3: 19%, n=4: 55%)
and the intraductal carcinoma (T2) four polysomic popula-
tions (n=3: 8%, n=5: 14%, n=6: 8%, n>6: 19%).
Discussion
In this study we report a constitutional point mutation at
codon 278 in exon 8 of the TP53 tumour-suppressor gene in
a patient with multiple primary malignancies. This particular
mutation has not yet been reported as a germ-line mutation.
The mutant allele was also detected in the PBLs-DNA of the
patient's two sons, but not in the other family members
tested. The patient's aunt and five siblings carry this allele in
a non-mutated form, which corroborates the hypothesis of a
de novo mutation and suggests that the patient is the founder
of a new cancer-prone family.
Codon 278 is not a mutational hot spot in sporadic cancer.
Reviewing over 2500 cases of TP53 mutations, Hollstein et
al. (1994) found only 31 mutations at codon 278 and three
C--T transitions at position 2 (Sameshima et al., 1992;
Hollstein et al., 1990).
The C-+T transition at position 2 is located in the DNA-
binding domain (Cho et al., 1994) and results in an amino
acid exchange from proline to leucine. It is likely that this
exchange has an influence on the protein structure, since
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Figure 2 Pedigree. Circles represent females and squares represent males. Semi-solid symbols represent mutation carriers and dash
is for deceased. The patient affected by multiple tumours (O) is indicated by an arrow. Haplotypes were derived from analysis of
polymorphic loci TP53 and D17S768. The proband inherited allele A from her father and allele B from her mother; her aunt
carrying the same allele B. The proband's mother's genotype is shown in parenthesis since it could not be analysed directly. It was
reconstituted by allelotyping the patient's father, her aunt and seven siblings. Since allele B was found in non-mutated form in the
aunt and five siblings, the TP53 germ-line mutation is classified de novo. The mutated allele (B) was transmitted to the patient's two
sons (o) (age 20 and 23), who showed no evidence of disease at time of analysis.
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Figure 3 Analysis ofpolymorphic loci TP53 (a) and D17S768 (b)
indicating LOH at TP53 for tumours TI, T2, T4, T5 and T6 and
at D17S768 for TI, T4, T5 and T6. An allelic imbalance factor
> 1.5 calculated for the peaks in the tumour samples in relation
to the peaks in the PBL-control (N) was chosen as an indication
for LOH. Note that there are many shadow peaks that are
thought to be most probably caused by erroneous nucleotide
incorporation by Taq Polymerase, which may occur when the
repeat unit is small, as is the case with the dinucleotide
polymorphisms shown.
leucine is much more hydrophobic than proline and is more
often found in the core region. This is the first report to
demonstrate that this particular mutation alters the half-life
of the protein. All tumour samples analysed showed positive
staining on immunohistochemistry, excluding the possibility
of a rare polymorphism. Although there are slight differences
in the staining intensity and the proportion of p53-positive
nuclei in the group of tumours examined (Table I), the
positive uniformity and the substantial number of positive
nuclei clearly indicate that the germ-line mutation in this case
is associated with conformational changes in the p53 protein,
its stabilization and potential loss of its function.
Five of the seven tumours showed LOH at and near the
TP53 locus as concordantly determined by microsatellite
analysis and PCR-TGGE (Table I, Figures 1 and 3). This is
in accordance with Knudson's two-hit hypothesis for the role
of tumour-suppressor genes in neoplasia (Knudson, 1985). In
the case of the pelvic recurrence of malignant histiocytoma
(T6), the entire wild-type chromosome had been lost in
approximately 40% of tumour cells as detected by FISH,
explaining the allelic loss detected by TGGE and micro-
satellite analyses. In the intraductal carcinoma of the left
breast (T2), LOH was found only at the TP53 locus but not
at the neighbouring locus D17S768, indicating that only a
short DNA region was affected. However, the calculated
imbalance factor for D17S768 was just slightly below the cut-
off level for LOH, possibly indicating a sensitivity problem in
detecting LOH for this locus in this tumour. This may either
be caused by a low number of tumour cells in the tissue
sample, or it may reflect the heterogeneity within a tumour,
indicating that LOH may be a dynamic process during
tumour progression. There is yet another indication that loss
of the non-mutated allele is not the only fundamental basis
for tumour development in this patient. In the Paget's disease
accompanied by a ductal carcinoma in situ of the right breast
(T3) and in the metastasis of an adenocarcinoma of unknown
origin (T7), no LOH was detected by any of the methods
used. However, positive immunohistochemical staining was
seen in these tumour samples. It has previously been shown
that in affected Li-Fraumeni family members a point
mutation in TP53 is insufficient for positive immunohisto-
chemical staining in non-tumoral tissue (Eeles et al., 1993;
Malkin et al., 1990). Therefore positive staining in the
tumours without LOH cannot only be related to the point
mutation, but also to a possible complexation of the wild-
type p53 by a protein like MDM2 (Momand et al., 1992;
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Oliner et al., 1992). Interference with such a protein would
probably affect p53 activity, thus being the proposed 'second
hit'. However, the nature of such another fundamental event
apart from the point mutation is unclear at present.
The finding of a marked chromosome 17 heterogeneity
with several separate polysomic populations in two tumours
is consistent with the postulated role of p53 in terms of
preserving genomic stability. This is in line with our findings
that more than three polysomic populations occur almost
exclusively in tumours with a p53 alteration (Sauter et al..
1995b).
There is strong evidence that some germ-line TP53
mutations are closely related to cancer development in their
carriers, because in p53 families early cancer development is
associated with the presence of the germ-line mutation. To
this point, we have not yet been able to prove that cancer in
our patient was indeed caused by the constitutional TP53
mutation but we believe that there is ample evidence to
support this notion: (1) the affected codon lies in a highly
conserved domain: (2) the mutation leads to an amino acid
exchange in the DNA-binding domain, resulting in a
conformational change and in stabilisation of the protein;
(3) the mutation seems to play a role in the development of
sporadic cancer; (4) frequent loss of the wild-type allele in the
tumours has been demonstrated; and (5) the mutant allele
coincides with the development of multiple primary cancers.
Reviewing the spectrum of tumours and the age of onset
that were reported in TP53 germ-line mutation carriers. Birch
et al. (1994) separated classical Li-Fraumeni syndrome
families from families exhibiting some but not all of the
features of Li-Fraumeni syndrome. In classical Li-
Fraumeni syndrome families, TP53 germ-line mutations are
much more common than in other cancer-prone families. As
to the histological type of her tumours. our patient fits into
both groups described. The future family history will decide
to which of the two groups they actually belong.
AckDowledgements
We are grateful to Dr Joe W Gray (Director of the UCSF
Resource for Molecular Genetics), who has generously supplied
the p17H8 probe (chromosome 17 centromere): we are also
grateful to Ms M Hedvika (University. Bern) and Mr L Szabo
(University, Vienna) and Mr R Kurzbauer (Institute of Molecular
Pathology, Vienna) for technical assistance. This work was
supported by the 'Medizinish-Wissenschaftlicher Fonds des
Birgermeisters der Bundeshauptstadt Wien and the Grant
Agency of the Czech Republic (grant no. 312 93 2329).
References
BIRCH JM. HARTLEY AL. TRICKER KJ. PROSSER J. CONDIE A.
KELSEY AM. HARRIS M. JONES PH. BINCHY A. CROWTHER D.
CROWTHER D. CRAFT AW. EDEN OB. EVANS GR. THOMPSON E.
MANN JR, MARTIN J. MITCHELL LD AND SANTIBANEZ-KOREF
MF. (1994). Prevalence and diversity of constitutional mutations
in the p53 gene among 21 Li-Fraumeni families. Cancer Res.. 54,
1298- 1304.
CARON DE FROMENTEL C AND SOUSSI T. (1992). TP53 tumor
suppressor gene: a model for investigating human mutagenesis.
Genes Chrom. Cancer. 4, 1 - 15.
CHO Y. GORINA S. JEFFREY PD AND PAVLETICH NP. (1994).
Crystal structure of a p53 tumor suppressor-DNA complex:
understanding tumorigenic mutations. Science. 265, 346-355.
EELES RA. WARREN W. KNEE G. BARTEK J. AVERILL D.
STRATTON MR. BLAKE PR. TAIT DM. LANE DP. EASTON DF.
YARNOLD JR. COOPER CS AND SLOANE JP. (1993). Constitu-
tional mutation in exon 8 of the p53 gene in a patient with
multiple primary tumours: molecular and immunohistochemical
findings. Oncogene, 8, 1269-1276.
GREENWALD BD. HARPAZ N. YIN J. HUANG Y. TONG Y. BROWN
VL. MCDANIEL T. NEWKIRK C. RESAU JH AND MELTZER SJ.
(1992). Loss ofheterozygosity affecting the p53, Rb, and mcc apc
tumor suppressor gene loci in dysplastic and cancerous ulcerative
colitis. Cancer Res.. 52, 741 -745.
GYAPAY G. MORISSETTE J. VIGNAL A. DIB C. FIZAMES C.
MILLAUSSEAU P. MARC S. BERNARDI G. LATHROP M AND
WEISSENBACH J. (1994). The 1993 -94 Genethon human genetic
linkage map. Vature Genet.. 7, 246-339.
HOLLSTEIN M. RICE K. GREENBLATT MS. SOUSSI T. FUCHS R.
SORLIE T. HOVIG E, SMITH SORENSEN B. MONTESANO R AND
HARRIS CC. (1994). Database of p53 gene somatic mutations in
human tumors and cell lines. Nucleic Acids Res., 12, 3551-3555.
HOLLSTEIN MC. METCALF RA. WELSH JA. MONTESANO R AND
HARRIS CC. (1990). Frequent mutation ofthe p53 gene in human
esophageal cancer. Proc. Natl Acad. Sci. USA, 87, 9958-9961.
JONES MH AND NAKAMURA Y. (1992). Detection of loss of
heterozygosity at the human TP53 locus using a dinucleotide
repeat polymorphism. Genes Chrom. Cancer. 5, 89-90.
KNUDSON AG. (1985). Hereditary cancer. oncogenes. and anti-
oncogenes. Cancer Res.. 45, 1437- 1443.
LANE DP. (1992). p53. guardian ofthe genome. Nature. 358, 15- 16.
LEVINE AJ. MOMAND J AND FINLAY CA. (1991). The p53 tumour
suppressor gene. Nature. 351, 453-456.
LI FP AND FRAUMENI JFJ. (1969). Soft-tissue sarcomas. breast
cancer, and other neoplasms. A familial syndrome? Ann. Intern.
Med., 71, 747-752.
MALKIN D. LI FP. STRONG LC. FRAUMENI JF Jr. NELSON CE. KIM
DH. KASSEL J. GRYKA MA. BISCHOFF FZ. TAINSKY M AND
FRIEND SH. (1990). Germ line p53 mutations in a familial
syndrome of breast cancer, sarcomas, and other neoplasms.
Science. 250, 1233 - 1238.
MIDGLEY CA, FISHER CJ. BARTEK J. VOJTESEK B. LANE D AND
BARNES DM_ (1992). Analysis of p53 expression in human
tumours: an antibody raised against human p53 expressed in
Escherichia coli. J. Cell. Sci.. 101, 183- 189.
MOMAND J. ZAMBETTI GP. OLSON DC. GEORGE D AND LEVINE.
Ai (1992). The mdm-2 oncogene product forms a complex with
the p53 protein and inhibits p53-mediated transactivation. Cell.
69, 1237- 1245.
OLINER JD. KINZLER KW. MELTZER PS. GEORGE DL AND
VOGELSTEIN. B. (1992). Amplification of a gene encoding a
p53-associated protein in human sarcomas. Nature, 358, 80-83.
SAMESHIMA Y. MATSUNO Y. HIROHASHI S. SHIMOSATO Y.
MIZOGUCHI H. SUGIMURA T. TERADA M AND YOKOTA J.
(1992). Alterations ofthe p53 gene are common and critical events
for the maintenance of malignant phenotypes in small-cell lung
carcinoma. Oncogene, 7, 451-457.
SAUTER G. MOCH H. CARROLL P. KERSCHMANN R. MIHATSCH
MSJ AND WALDMANN FW. (1995a). Chromosome-9 loss detected
by fluorescence in situ hybridisation in bladder cancer. Int. J.
Cancer. 64, 99- 103.
SAUTER G. MOCH H. GASSER TH. MIHATSCH MJ AND WALDMAN
FM. (1995b). Heterogeneity of chromosome 17 and erbB-2 gene
copy number in primary and metastatic bladder cancer.
Cytometry. 21, 40-46.
SHEFFIELD VC. COX DR. LER.MAN LS AND MYERS R.M. (1989).
Attachment ofa 40-base-pair G +C-rich sequence (GC-clamp) to
genomic DNA fragment by the polymerase chain reaction results
in improved detection of single-base changes. Proc. Natl Acad.
Sci. LSA. 86, 232-236.
SOUSSI T. CARON DE FROM-ENTEL C AND MAY P. (1990).
Structural aspects of the p53 protein in relation to gene
evolution. Oncogene. 5, 945-952.
SPEISER P. GHAREHBAGHI-SCHNELL E. SCHNEEBERGER C. EDER
S AND ZEILLINGER R. (1996). Microdissection as a means to
verify allelic imbalance in tumor biopsy samples. Anticancer Res..
16, 461-464.
SRIVASTAVA S. ZOU ZQ. PIROLLO K. BLATTNER W AND CHANG
EH. (1990). Germ-line transmission of a mutated p53 gene in a
cancer-prone family with Li-Fraumeni syndrome. Nature. 348,
747- 749.
VOGELSTEIN B AND KINZLER KW. (1992). p53 function and
dysfunction. Cell. 70, 523 -526.
VOJTESEK B. BARTEK J. M.IDGLEY CA AND LANE DP. (1992). An
immunochemical analysis of the human nuclear phosphoprotein
p53. New monoclonal antibodies and epitope mapping using
recombinant p53. J. Immunol. .Methods, 151, 237-244.
ZAKUT HOURI R. BIENZ TADMOR B. GIVOL D AND OREN M.
(1985). Human p53 cellular tumor antigen: cDNA sequence and
expression in COS cells. EMBO J., 4, 1251 - 1255.